WO2005123111A3 - Maxs as modifiers of the axin pathway and methods of use - Google Patents

Maxs as modifiers of the axin pathway and methods of use Download PDF

Info

Publication number
WO2005123111A3
WO2005123111A3 PCT/US2005/021679 US2005021679W WO2005123111A3 WO 2005123111 A3 WO2005123111 A3 WO 2005123111A3 US 2005021679 W US2005021679 W US 2005021679W WO 2005123111 A3 WO2005123111 A3 WO 2005123111A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
axin
maxs
modifiers
axin pathway
Prior art date
Application number
PCT/US2005/021679
Other languages
French (fr)
Other versions
WO2005123111A2 (en
Inventor
Steven Brian Gendreau
Emery G Dora Iii
Monique Nicoll
Original Assignee
Exelixis Inc
Steven Brian Gendreau
Emery G Dora Iii
Monique Nicoll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Steven Brian Gendreau, Emery G Dora Iii, Monique Nicoll filed Critical Exelixis Inc
Publication of WO2005123111A2 publication Critical patent/WO2005123111A2/en
Publication of WO2005123111A3 publication Critical patent/WO2005123111A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

Human MAX genes are identified as modulators of the AXIN pathway, and thus are therapeutic targets for disorders associated with defective AXIN function. Methods for identifying modulators of AXIN, comprising screening for agents that modulate the activity of MAX are provided.
PCT/US2005/021679 2004-06-21 2005-06-20 Maxs as modifiers of the axin pathway and methods of use WO2005123111A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58168004P 2004-06-21 2004-06-21
US60/581,680 2004-06-21

Publications (2)

Publication Number Publication Date
WO2005123111A2 WO2005123111A2 (en) 2005-12-29
WO2005123111A3 true WO2005123111A3 (en) 2006-07-06

Family

ID=35510262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021679 WO2005123111A2 (en) 2004-06-21 2005-06-20 Maxs as modifiers of the axin pathway and methods of use

Country Status (1)

Country Link
WO (1) WO2005123111A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101989A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101989A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KORSWAGEN H.C. ET AL.: "The Axin-like protein PRY-1 is a negative regulator of a canonical Wnt Pathway in C. elegants", GENES & DEV., vol. 16, 2002, pages 1291 - 1302, XP002903540 *
MORISHITA R. ET AL.: "INTIMAL HYPERPLASIA AFTER VASCULAR INJURY IS INHIBITED BY ANTISENSE CDK 2 KINASE OLIGONUCLEOTIDES", J. CLIN. INVEST., vol. 93, 1994, pages 1458 - 1464, XP000914198 *

Also Published As

Publication number Publication date
WO2005123111A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2007002188A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2006009928A3 (en) Galnts as modifiers of the igfr pathway and methods of use
WO2005072475A3 (en) Itpks as modifiers of the igfr pathway and methods of use
WO2006036613A3 (en) Mracs as modifiers of the rac pathway and methods of use
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005003297A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2006099182A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use
WO2006009960A3 (en) Hdacs as modifiers of the rb pathway and methods of use
WO2007002081A3 (en) Gfats as modifiers of the axin pathway and methods of use
WO2005123111A3 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004013308A3 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004015073A3 (en) MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004005486A3 (en) Mp21s as modifiers of the p21 pathway and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2007058860A3 (en) Mrhos as modifiers of the rho pathway and methods of use
WO2008036422A3 (en) Vipr1s as modifiers of the e2f/rb pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase